Skip to main content
TRAX $44.88 +0.85%
TRAX logo
TRAX · First Tracks Biotherapeutics, Inc.
Track TRAX — free
$44.88 +0.38 (+0.85%)
Market Cap
$1.87B
Shares
42.02M
Volume · Nov 19 103.86K Avg daily vol (3M) 827.63K
All webcasts

Earnings call · FY2026 Q3

First Tracks Biotherapeutics, Inc. (TRAX) Q3 2026 Earnings Call

Concluded Oct 12, 2026
Oct 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$0.88
Net income -$31.36M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 3, 2026
First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.
10-Q report · filed Nov 3, 2026
First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document